CMAP

(redirected from Compound Muscle Action Potential)
AcronymDefinition
CMAPChicago Metropolitan Agency for Planning (Chicago, IL)
CMAPConference Manager Access Protocol
CMAPColor Map
CMAPCompound Muscle Action Potential (aka Compound Motor Action Potential; neurophysiology)
CMAPCharacter Map
CMAPCancer Molecular Analysis Project (US NIH)
CMAPCover My Ass Partner
CMAPClimate Modeling, Analysis & Prediction (NSF)
CMAPCoherent Multiarray Processing
CMAPCombat Military Appreciation Process (Australian Army)
References in periodicals archive ?
Decrement in repetitive stimulation denotes the maximum decrease in amplitude of the fourth or fifth compound muscle action potential waveform during supramaximal repetitive nerve stimulation at 3 Hz.
Nerve conduction study abnormalities of syringomyelia include low amplitude compound muscle action potential, loss of F response or low amplitude F response with delayed latency.
[4] Demyelination of motor neuron leads to decrease in CV with relative sparing in the amplitude of the compound muscle action potential (CMAP) with stimulus distal to the site of lesion.
In the article titled "Mechanism of Restoration of Forelimb Motor Function after Cervical Spinal Cord Hemisection in Rats: Electrophysiological Verification" [1], there were errors in the compound muscle action potential (CMAP) results reported in the Rats for Hemisection section, Table 1, and Figure 9, as follows:
Compound muscle action potential (CMAP) (normal > 6.8 mV), motor nerve conduction velocity (M-NCV) (normal > 49.4 m/sec), motor distal latency (normal < 3.8 msec), sensory nerve action potential (SNAP) (normal > 10 [micro]V), and sensory nerve conduction velocity (SNCV) (normal > 40.4 m/sec) were measured.
The electroneuronographic studies of 11 and 25 November 2014 showed significantly decreased compound muscle action potential (CMAP) amplitudes and preserved sensory nerve action potential (SNAP) amplitudes, with normal distal latencies and conduction velocities, favouring a diagnosis of an AMAN variant of the Guillain-Barre syndrome (Tables 2 and 3).
Electrophysiological studies in May 2012 showed slowed motor conduction velocities and reduced compound muscle action potential amplitudes in the Peroneal, Tibial and Ulnar nerves bilaterally.
Similarly, in the same Phase 1/2 trial, the IT transplanted patients also showed indications of neurotrophic and regenerative effects, as evidenced by an increase in Compound Muscle Action Potential (CMAP) in the treated arm.
Both CVmax and CVmin were calculated from the difference in latencies of the compound muscle action potential (M waves) when the nerve was stimulated appropriately at the proximal and distal sites, divided by the distance between the two sites.
Structures were explored with stimulation using 0.7 mA of current for 0.2 ms duration, but a compound muscle action potential (CMAP) was not produced and the surgeon could not visualize the recurrent laryngeal nerves because that area of the neck was avoided during surgery.
Right tibialis anterior compound muscle action potential (CMAP) was evoked by peroneal nerve stimulation.